Daiichi Sankyo
Maria Lizza Bowen has extensive work experience in the pharmaceutical industry. Maria Lizza currently holds the position of Chief Of Staff Sr. Director Clinical Science at Daiichi Sankyo, Inc. and has been with the company since 2016. Prior to this role, they served as Director, Clinical Development, Patient Safe Use and Director, Cancer Enterprise Development Operations at the same company. Before joining Daiichi Sankyo, Inc., Maria worked as an Associate Director, Clinical Operations, Oncology at another pharmaceutical company. Outside of the pharmaceutical industry, they are also a Book Author, having published books under the name "Books by Maria" since 2022. Prior to their current roles, they worked as a Consultant and Director of Clinical Services at QSC, Inc., a Clinical Research Scientist at Celgene, and a Clinical Trial Head at Novartis. Maria Lizza began their career at Sanofi Pasteur, where they held roles as a Clinical Research Associate and Sr. Laboratory Technician. Maria has a strong background in clinical research and development within the pharmaceutical industry.
Maria Lizza Bowen earned a Bachelor of Science degree with a concentration in Biology from the University of Scranton, completing their studies from 1990 to 1995.
This person is not in any teams
This person is not in any offices
Daiichi Sankyo
21 followers
Daiichi Sankyo Co., Ltd. engages in the research, development, manufacture, and sale of pharmaceutical products. It operates through the following segments: Daiichi Sankyo Group and Ranbaxy Group. The Daiichi Sankyo Group segment comprises of Daiichi Sankyo Co., Ltd. and its subsidiaries. The Ranbaxy Group segment includes its core company, Ranbaxy Laboratories Ltd. Both group segments deal with business activities in prescription drugs and general pharmaceutical products. The company was founded on September 28, 2005 and is headquartered in Tokyo, Japan.